English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  To assess the relationship between weight change and glycated haemoglobin ( HbA1c ) change in dulaglutide‐treated patients by analysing data from six head‐to‐head phase  III AWARD  clinical trials.    Methods  At 26 weeks, the relationship between weight and  HbA1c  was analysed in each trial rather than by pooling data because of differences in design and background therapy. The effect of baseline characteristics was also evaluated with regard to weight and  HbA1c  response.    Results  Across the studies, 87–97% and 83–95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in  HbA1c  levels, while 57–88% and 43–84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss. The majority (55–83%) of patients receiving dulaglutide 1.5 mg experienced weight loss and  HbA1c  reductions, while 41–79% of patients in the dulaglutide 0.75 mg arm lost weight and had reductions in  HbA1c  level. A weak and inconsistent correlation was observed between the changes in weight and  HbA1c  (range from −0.223 to 0.267) in patients treated with dulaglutide. The baseline characteristics of gender, age, duration of diabetes,  HbA1c , body weight and  BMI  were not related to different combinations of weight and  HbA1c  responses.    Conclusions  Dulaglutide is an effective treatment option across the type 2 diabetes treatment spectrum. Dulaglutide showed dose‐dependent effects on both weight loss and  HbA1c  reduction. These effects had a weak correlation and appeared to be independent.

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once‐weekly dulaglutide treatment